Bafna Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Bafna Pharmaceuticals has a total shareholder equity of ₹823.7M and total debt of ₹165.9M, which brings its debt-to-equity ratio to 20.1%. Its total assets and total liabilities are ₹1.3B and ₹525.1M respectively. Bafna Pharmaceuticals's EBIT is ₹119.9M making its interest coverage ratio 5.9. It has cash and short-term investments of ₹78.6M.
Key information
20.1%
Debt to equity ratio
₹165.85m
Debt
Interest coverage ratio | 5.9x |
Cash | ₹78.64m |
Equity | ₹823.66m |
Total liabilities | ₹525.05m |
Total assets | ₹1.35b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 532989's short term assets (₹909.5M) exceed its short term liabilities (₹442.2M).
Long Term Liabilities: 532989's short term assets (₹909.5M) exceed its long term liabilities (₹82.8M).
Debt to Equity History and Analysis
Debt Level: 532989's net debt to equity ratio (10.6%) is considered satisfactory.
Reducing Debt: 532989's debt to equity ratio has reduced from 198.1% to 20.1% over the past 5 years.
Debt Coverage: 532989's debt is well covered by operating cash flow (93.5%).
Interest Coverage: 532989's interest payments on its debt are well covered by EBIT (5.9x coverage).